To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Inclusion Criteria

• •1. Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
• •2. Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
• •3. Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
• •4. Patients initiating Zepzelca treatment in second-line.
• •5. Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression.
• •6. Eastern Cooperative Oncology Group performance status (ECOG) ≤1